尼妥珠单抗联合化疗治疗晚期消化道肿瘤临床疗效观察

目的观察尼妥珠单抗联合化疗治疗晚期消化道肿瘤的近期疗效及患者不良反应。方法观察组：22例确诊的晚期消化道肿瘤患者，其中食管癌10例，胃癌6例，胰腺癌4例，胆管癌2例。给予尼妥珠单抗联合化疗治疗，尼妥珠单抗每周给予200mg，至少完成6周。对照组：21例患者，其中食管癌10例，胃癌6例，胰腺癌3例，胆管癌2例，应用尼妥珠单抗治疗至少6周。结果观察组有效率（RR）31．8％（7／22），疾病控制率（DCR）72．7％（16／22），对照组RR14．3％（3／21），DCR42．8％（9／21）．两组间DCR及QOL改善比较差异有统计学意义（Х^2=3．939，Х^2=4．250，均P〈0．05）。在RR及主要不良反应方面两组的差异无统计学意义。结论尼妥珠单抗联合化疗治疗晚期消化道肿瘤疗效较好，可以提高疾病控制率，不良反应可耐受，生活质量得到改善。

Clinical observation of nimotuzumab with chemotherapy in metastatic gastrointestinal tumor patients

Objeetive To explore the efficacy and toxicity of nimotuzumab plus chemotherapy in the treatment of metastatic gastrointestinal tumor. Methods Observation group 22 patients with metastatic gastrointestinal tumor with confirmed diagnosis , were treated with nimotuzumab in combination chemotherapy. Nimotuzumab was given 200 mg weekly for at least six weeks. Control group 21 patients with metastatic gastrointestinal tumor with confirmed diagnosis were treated with only chemotherapy. Results The effects of observation group could be observed in 22 patients, the rate of response （RR） was 31.8% （7/22）, and the disease control rate （DCR） was 72.7 % （16/22）. QOL was improved. The effects of observation group could be observed in 21 patients, RR was 14.3 % （3/21）, and the disease control rate was 42.8 % （19/21）. DCR and QOL improvements were statistically significant different between the two groups. （Х^2 = 3.939, Х^2 = 4.250,P 〈 0.05）.The two groups had no significant difference in RR and toxicity. Conclusion Nimotuzumab in combination with chemotherapy is effective and can improve the disease control rate, toxicity, tolerance, quality of life.